Cargando…

Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy

BACKGROUND: No pan-cancer study has been conducted till date to explore the comprehensive oncogenic roles of pyruvate kinase M2 (PKM2). METHODS: TCGA, TIMER, GEPIA, UALCAN, STRING, and other databases were used to analyze the expression, prognostic roles, epigenetic variants, and possible oncogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Nan, Mi, Lusi, Li, Jingting, Li, Tong, Chen, Jun, Dionigi, Gianlorenzo, Guan, Haixia, Sun, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974260/
https://www.ncbi.nlm.nih.gov/pubmed/36865483
http://dx.doi.org/10.1155/2023/3375109
_version_ 1784898690067988480
author Liang, Nan
Mi, Lusi
Li, Jingting
Li, Tong
Chen, Jun
Dionigi, Gianlorenzo
Guan, Haixia
Sun, Hui
author_facet Liang, Nan
Mi, Lusi
Li, Jingting
Li, Tong
Chen, Jun
Dionigi, Gianlorenzo
Guan, Haixia
Sun, Hui
author_sort Liang, Nan
collection PubMed
description BACKGROUND: No pan-cancer study has been conducted till date to explore the comprehensive oncogenic roles of pyruvate kinase M2 (PKM2). METHODS: TCGA, TIMER, GEPIA, UALCAN, STRING, and other databases were used to analyze the expression, prognostic roles, epigenetic variants, and possible oncogenic mechanisms of PKM2. Proteomic sequencing data and PRM were applied to validate. RESULTS: PKM2 showed higher expression in majority of cancers, the expression being significantly correlated with the clinical stage. Higher expression of PKM2 was associated with lower OS and DFS in several cancers, such as MESO and PAAD. In addition, the epigenetic variation of PKM2, including gene alteration, mutation type and sites, DNA methylation, and phosphorylation, showed diversity in different cancers. All four methods indicated that PKM2 is positively associated with the immune infiltration of tumor-associated fibroblasts, such as in THCA, GBM, and SARC. Further mechanistic exploration suggested that the ribosome pathway might play an essential role in the regulation of PKM2, and interestingly, four out of ten hub genes were found to be highly related to OS in several cancers. Finally, in thyroid cancer specimen, we validated the expression and potential mechanisms by proteomic sequencing and PRM validation. CONCLUSION: In the majority of cancers, the higher expression of PKM2 was highly associated with poor prognosis. Further molecular mechanism exploration implied that PKM2 might serve as a potential target for cancer survival and immunotherapy by regulating the ribosome pathway.
format Online
Article
Text
id pubmed-9974260
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-99742602023-03-01 Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy Liang, Nan Mi, Lusi Li, Jingting Li, Tong Chen, Jun Dionigi, Gianlorenzo Guan, Haixia Sun, Hui Biomed Res Int Research Article BACKGROUND: No pan-cancer study has been conducted till date to explore the comprehensive oncogenic roles of pyruvate kinase M2 (PKM2). METHODS: TCGA, TIMER, GEPIA, UALCAN, STRING, and other databases were used to analyze the expression, prognostic roles, epigenetic variants, and possible oncogenic mechanisms of PKM2. Proteomic sequencing data and PRM were applied to validate. RESULTS: PKM2 showed higher expression in majority of cancers, the expression being significantly correlated with the clinical stage. Higher expression of PKM2 was associated with lower OS and DFS in several cancers, such as MESO and PAAD. In addition, the epigenetic variation of PKM2, including gene alteration, mutation type and sites, DNA methylation, and phosphorylation, showed diversity in different cancers. All four methods indicated that PKM2 is positively associated with the immune infiltration of tumor-associated fibroblasts, such as in THCA, GBM, and SARC. Further mechanistic exploration suggested that the ribosome pathway might play an essential role in the regulation of PKM2, and interestingly, four out of ten hub genes were found to be highly related to OS in several cancers. Finally, in thyroid cancer specimen, we validated the expression and potential mechanisms by proteomic sequencing and PRM validation. CONCLUSION: In the majority of cancers, the higher expression of PKM2 was highly associated with poor prognosis. Further molecular mechanism exploration implied that PKM2 might serve as a potential target for cancer survival and immunotherapy by regulating the ribosome pathway. Hindawi 2023-02-21 /pmc/articles/PMC9974260/ /pubmed/36865483 http://dx.doi.org/10.1155/2023/3375109 Text en Copyright © 2023 Nan Liang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liang, Nan
Mi, Lusi
Li, Jingting
Li, Tong
Chen, Jun
Dionigi, Gianlorenzo
Guan, Haixia
Sun, Hui
Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy
title Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy
title_full Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy
title_fullStr Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy
title_full_unstemmed Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy
title_short Pan-Cancer Analysis of the Oncogenic and Prognostic Role of PKM2: A Potential Target for Survival and Immunotherapy
title_sort pan-cancer analysis of the oncogenic and prognostic role of pkm2: a potential target for survival and immunotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974260/
https://www.ncbi.nlm.nih.gov/pubmed/36865483
http://dx.doi.org/10.1155/2023/3375109
work_keys_str_mv AT liangnan pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy
AT milusi pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy
AT lijingting pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy
AT litong pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy
AT chenjun pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy
AT dionigigianlorenzo pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy
AT guanhaixia pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy
AT sunhui pancanceranalysisoftheoncogenicandprognosticroleofpkm2apotentialtargetforsurvivalandimmunotherapy